Bristol-Myers Squibb

Home

Understanding HCM

Our Pipeline

Bristol Myers Squibb

Mavacamten MOA

This site is intended for US Health Care Professionals only.

Pipeline

BMS* Cardiovascular Pipeline

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Information as of August 2021.

Phase 1

FPR-2 Agonist1

(BMS-986235)2

Heart failure

Cardiac Myosin Inhibitor1

Hypertrophic cardiomyopathy

ROMK Inhibitor1

Heart failure

FXIa Inhibitor1

Thrombotic disorders

Phase 2

Mavacamten1

(MYK-461)3

Non-obstructive hypertrophic cardiomyopathy

Mavacamten1

(MYK-461)3

Heart failure with preserved ejection fraction

FA-Relaxin1

(BMS-986259)6

Heart failure

Milvexian†1

(BMS-986177)4

Thrombotic disorders

Danicamtiv1

(MYK-491)5

Genetic dilated cardiomyopathy

Apixaban‡1

Pediatric heart disease

Phase 3

Mavacamten1

(MYK-461)3

Obstructive hypertrophic cardiomyopathy

Apixaban‡1

VTE prevention in pediatrics with ALL

Mavacamten1

(MYK-461)3

Obstructive hypertrophic cardiomyopathy patients eligible for SRT

*and collaborators

†Milvexian is being developed in partnership with Janssen Pharmaceuticals, Inc

‡Apixaban is being developed in these areas in partnership with Pfizer, Inc

ALL, acute lymphoblastic leukemia; VTE, venous thromboembolism; SRT, septal reduction therapy

1Bristol Myers Squibb. In the pipeline. https://www.bms.com/researchers-and-partners/in-the-pipeline.html. Accessed August 3, 2021.

2Clinicaltrials.gov identifier: NCT03335553. Updated August 11, 2020. Accessed August 19, 2021. https://clinicaltrials.gov/ct2/show/study/NCT03335553.

3Clinicaltrials.gov identifier: NCT03442764. Updated October 19, 2020. Accessed August 19, 2021. https://clinicaltrials.gov/ct2/show/NCT03442764.

4Clinicaltrials.gov identifier: NCT04844424. Updated July 23, 2021. Accessed August 19, 2021. https://clinicaltrials.gov/ct2/show/NCT04844424.

5Clinicaltrials.gov identifier: NCT04572893. Updated August 12, 2021. Accessed August 19, 2021. https://clinicaltrials.gov/ct2/show/NCT04572893.

6Clinicaltrials.gov identifier: NCT04318093. Updated February 10, 2021. Accessed August 19, 2021. https://clinicaltrials.gov/ct2/show/NCT04318093.

Bristol-Myers Squibb

© 2021 MyoKardia, Inc, a wholly owned subsidiary of Bristol-Myers Squibb™. All rights reserved. CV-US-2100443 08/21